Company Developments - Stereotaxis, Inc. has received its first order for the GenesisX robotic system from a European hospital, marking a significant step in expanding the adoption of robotics in endovascular interventions [1][3] - GenesisX, which has received CE Mark approval in Europe and is pending FDA clearance, is designed to simplify installation and operational requirements, making it more accessible for hospitals [3][5] - The system is smaller and lighter than previous models, requiring no structural anchoring and operating on standard power outlets, which enhances its usability in operating rooms [6] Financial Performance - Stereotaxis has a market capitalization of $205.1 million, with a Zacks Consensus Estimate indicating a 37.2% year-over-year increase in fiscal 2025 earnings, alongside a 67.5% revenue improvement [4] Industry Prospects - The global surgical robots market is projected to grow from $9.6 billion in 2023 to $23.7 billion by 2029, reflecting a compound annual growth rate of 16.6% [8] - The demand for minimally invasive surgery is increasing due to its benefits, such as improved precision and shorter hospital stays, which is driving market expansion [9] Recent Innovations - In January, Stereotaxis received CE Mark approval for the MAGiC ablation catheter, which is designed for cardiac ablation procedures, further establishing its presence in the robotics field [10]

Core Viewpoint - Stereotaxis will announce its financial results for the fourth quarter and full year of 2024 on March 3, 2025, before the U.S. financial markets open, followed by a conference call to discuss the results and corporate developments [1]. Group 1: Financial Results Announcement - The financial results for the fourth quarter and full year of 2024 will be released on March 3, 2025 [1]. - A conference call and webcast will take place at 8:30 a.m. ET on the same day to discuss the results [1][2]. Group 2: Company Overview - Stereotaxis is a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention [3]. - The company's mission focuses on the discovery, development, and delivery of robotic systems, instruments, and information solutions for interventional laboratories [3]. - Stereotaxis technology has been utilized to treat over 150,000 patients globally, enhancing patient care with robotic precision and safety [3].

Core Insights - Stereotaxis has received its first order for the GenesisX robotic system, marking a significant milestone towards its commercial launch [1][2] - The GenesisX system enhances the accessibility of Robotic Magnetic Navigation in endovascular surgery, featuring a compact design and requiring no structural anchoring [2][3] - The company aims to obtain regulatory approvals for GenesisX and compatible catheters in both Europe and the US during 2025 [3] Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, focusing on the development of robotic systems and solutions to improve patient care [4] - The technology has been utilized to treat over 150,000 patients globally, demonstrating its impact in the healthcare sector [4]

Core Insights - Stereotaxis has received European CE Mark approval for its MAGiC™ ablation catheter, marking a significant milestone in the field of surgical robotics for minimally invasive endovascular intervention [1][3][4] - The MAGiC catheter is designed for cardiac ablation procedures to treat heart arrhythmias, enhancing treatment precision and control while maintaining safety [2][3] - The approval follows extensive development, testing, and clinical research, indicating strong potential for broad adoption among robotic users [3][4] Company Overview - Stereotaxis is a pioneer in surgical robotics, focusing on minimally invasive endovascular interventions and has treated over 150,000 patients globally [5] - The company's mission includes the development of robotic systems and solutions that improve patient care and enhance operational efficiency in interventional laboratories [5] Product Features - The MAGiC catheter features optimized navigation, force, and stability through unique magnet placement and design [7] - It offers improved data and information capabilities with iConnect and eContact modules, providing critical contact and temperature data for physicians [7] - The catheter utilizes efficient low-flow uniform cooling to minimize fluid load on patients while preventing char and coagulation [7]

Company Overview - Stereotaxis is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention [4] - The company's mission is to discover, develop, and deliver robotic systems, instruments, and information solutions for the interventional laboratory [4] - Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere [4] Technological Advancements - Physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis [1] - The Genesis System introduces significant advances in Robotic Magnetic Navigation technology, offering precision and stability for cardiac ablation procedures [2][3] - Oulu University Hospital has treated over 2,000 patients with earlier versions of the technology, demonstrating significant experience in robotic heart rhythm treatments [2] Industry Impact - Robotic Magnetic Navigation technology enhances the precision and safety of cardiac ablation, a common minimally invasive procedure for treating arrhythmias [2] - Tens of millions of individuals worldwide suffer from arrhythmias, which can lead to serious health risks such as stroke, heart failure, and sudden cardiac arrest if left untreated [2] - The partnership between Stereotaxis and Oulu University Hospital aims to expand access to leading cardiac care in Finland [3] Leadership and Vision - David Fischel, Chairman and CEO of Stereotaxis, emphasized the company's commitment to enhancing and expanding its partnership with Oulu University to ensure access to advanced cardiac care [3] - Dr. Jarkko Magga, Cardiac Electrophysiologist at Oulu University, highlighted the importance of advanced robotic technology in providing superior patient care for complex cardiac arrhythmias [3]

Stereotaxis, Inc. (STXS) and Shanghai MicroPort EP Medtech Co., Ltd. announced the receipt of regulatory approval from China’s National Medical Products Administration (“NMPA”) for the Magbot Magnetic Navigation Ablation Catheter last Monday. Stereotaxis had previously announced its collaboration with MicroPort EP in August 2021.It is worthwhile to note that the Magbot Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed by MicroPort EP in collaboration ...

ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Neusoft Medical Systems Co., Ltd ("Neusoft Medical Systems") today announced that Stereotaxis' latest GenesisX robotic system is being featured for the first time at Neusoft Medical Systems' booth at the Radiology Society of North America's (RSNA) 2024 Annual Meeting taking place December 1-5 in Chicago, IL. RSNA is the premier annual radiology forum in the world, with over 50,000 attendees from over 150 countries. ...

In this article, I will provide my takeaways from Stereotaxis' (NYSE: STXS ) Q3 quarterly report & call, review points made at the SCRN (Society For Cardiac Robotic Navigation) conference, analyze a few new studies & a case study, look at MAGiC-FEST data from the Analyst's Disclosure: I/we have a beneficial long position in the shares of STXS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (o ...

Stereotaxis (STXS) and Shanghai MicroPort EP recently announced the regulatory approval of the Genesis Robotic Magnetic Navigation (RMN) System by China's National Medical Products Administration (NMPA). With this approval, MicroPort EP is likely to initiate a full commercial launch of Genesis through its existing sales teams focused on the electrophysiology community. NMPA's approval of the Genesis RMN System is a key element in a broader collaboration between Stereotaxis and MicroPort EP, which is likely ...

ST. LOUIS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 36th Annual Healthcare Conference. Mr. Fischel will deliver a formal presentation on Stereotaxis' technology and growth strategy on Thursday, December 5, 2024, at 2:00 pm ET. Mr. Fischel will be available for one-on-one meetings that same day. "This ...